Cancer Insights Session
Multianalyte Studies of Liquid Biopsies
Are you working with cell-free DNA, extracellular vesicles or circulating tumor cells (CTCs)? Have you ever asked yourself: Do we miss (or even waste) genomic and transcriptomic information by considering only one analyte? How would the picture change if all analytes could be investigated from the same sample?
In the ELIMA (Evaluation of multiple Liquid biopsy analytes In Metastatic breast cancer patients All from one blood sample) study, Sabine Kasimir-Bauer and Corinna Keup (University Hospital Essen, Germany) approached this challenge, established workflows and compared and analyzed RNA profiles of circulating tumor cells and extracellular vesicles, performed mutational analysis of cell-free DNA (cfDNA) from naïve or CTC-depleted plasma and more.
This Cancer Insights session features Science Talks with Sabine Kasimir-Bauer, Corinna Keup and an expert round with QIAGEN scientists. You can download your own poster guide to get started with Multianalyte Liquid Biopsies and access publications for further reading.
Read about the ELIMA studies
- Keup C. et al. (2018) RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients. Clinical Chemistry
- Keup C. et al. (2019) Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. Cellular and Molecular Life Sciences
- Keup C. et al. (2019) Cell-free DNA variant sequencing using CTC-depleted blood for comprehensive liquid biopsy testing in metastatic breast cancer Cancers
- Keup C. et al. (2020) Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients. Cancers